Free Trial
OTCMKTS:CVSI

CV Sciences (CVSI) Stock Price, News & Analysis

CV Sciences logo
$0.04 +0.00 (+2.01%)
As of 01/3/2025 05:40 PM Eastern

About CV Sciences Stock (OTCMKTS:CVSI)

Key Stats

Today's Range
$0.03
$0.04
50-Day Range
$0.03
$0.05
52-Week Range
$0.03
$0.10
Volume
239,871 shs
Average Volume
140,786 shs
Market Capitalization
$6.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

CV Sciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
1st Percentile Overall Score

CVSI MarketRank™: 

CV Sciences scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for CV Sciences.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CV Sciences is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CV Sciences is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CV Sciences has a P/B Ratio of 1.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.02% of the outstanding shares of CV Sciences have been sold short.
  • Short Interest Ratio / Days to Cover

    CV Sciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CV Sciences has recently increased by 363.29%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CV Sciences does not currently pay a dividend.

  • Dividend Growth

    CV Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.02% of the outstanding shares of CV Sciences have been sold short.
  • Short Interest Ratio / Days to Cover

    CV Sciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CV Sciences has recently increased by 363.29%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    1 people have searched for CVSI on MarketBeat in the last 30 days.
Receive CVSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter.

CVSI Stock News Headlines

CV Sciences to Acquire Extract Labs in $1.4M Deal
Stunning Trump Exec Order Leaked
This secret document contains stunning details about Donald Trump’s very first order of business… the minute he steps back into the White House. Because if what’s in this leaked document is even half true (and trust me, it comes from a very, very credible source)...
CV Sciences Reports Q3 Revenue and Product Launch
CV Sciences Reports Stable Q3 2024 Results
See More Headlines

CVSI Stock Analysis - Frequently Asked Questions

CV Sciences' stock was trading at $0.0338 at the start of the year. Since then, CVSI shares have increased by 5.0% and is now trading at $0.0355.
View the best growth stocks for 2025 here
.

CV Sciences, Inc. (OTCMKTS:CVSI) announced its quarterly earnings results on Thursday, August, 12th. The company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The company earned $5.13 million during the quarter, compared to analyst estimates of $5.12 million. CV Sciences had a negative trailing twelve-month return on equity of 101.85% and a negative net margin of 16.24%.

Shares of CVSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that CV Sciences investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Charlotte's Web (CWBHF), Cronos Group (CRON), KushCo (KSHB), NVIDIA (NVDA) and Organigram (OGI).

Company Calendar

Last Earnings
8/12/2021
Today
1/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:CVSI
Previous Symbol
NASDAQ:CVSI
Employees
70
Year Founded
N/A

Profitability

Net Income
$3.10 million
Pretax Margin
-16.26%

Debt

Sales & Book Value

Annual Sales
$16 million
Cash Flow
$0.02 per share
Book Value
$0.02 per share

Miscellaneous

Free Float
182,392,000
Market Cap
$6.56 million
Optionable
Not Optionable
Beta
0.66
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (OTCMKTS:CVSI) was last updated on 1/6/2025 by MarketBeat.com Staff
From Our Partners